Publications

Science Founded on Unique Insights, Powered by Groundbreaking Research

A collection of research papers, scientific publications and presentations relevant to our platform, processes and products.

Publications

Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting

Posoleucel, an Allogeneic, Off-the-Shelf Multi-Virus Specific T Cell Therapy, for Severe, Drug -Refractory Viral Infections in Pediatric Patients Following HCT: Results from a Phase 2 Trial

Allogeneic, Off-the-Shelf, SARS-CoV-2-Specific T Cells (ALVR109) for the Treatment of COVID-19 in High Risk Patients

Longitudinal Analysis of the Evolution of Cellular Immunity to SARS-CoV-2 Induced by Infection and Vaccination

Clinical Course of a Kidney Transplant Recipient with BK Polyomavirus Administered Posoleucel Multivirus Specific T Cells

Posoleucel as Preemptive Therapy for BKV Infection in Kidney Transplant Recipients: Safety, Tolerability and Efficacy in a Phase 2 Trial

Exploring Hepatitis B Virus as an Immunotherapeutic Target for Clinical Trials of Adoptively Transferred T Cells

Clinical and Economic Burden of Multiple dsDNA Viral Infections After Allogeneic Hematopoietic Cell Transplantation

Posoleucel as Preemptive Therapy for BKV Infection in Kidney Transplant Recipients: Safety and Tolerability in a Phase 2 Trial

Use of Targeted T-Cell Therapy (Posoleucel) for the Treatment of Epstein-Barr Virus Associated Leiomyosarcoma in an Adult Kidney Transplant Recipient: A Case Report

Early Clinical Experience with ALVR109, a Partially Hla-matched Sars-cov-2 Specific T-cell Therapy, in Immunocompromised Patients with COVID-19

Economic and Clinical Burden Associated with Respiratory Viral Infections After Allogeneic Hematopoietic Cell Transplant

Multivirus-Specific T-Cell Therapy with Posoleucel (ALVR105) for Refractory Disseminated Adenovirus Infection after Allogeneic HCT

Successful Treatment with ALVR105 for Disseminated Adenovirus Infection in an Infant after Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report

Posoleucel (ALVR105), an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Viral Infections Post-Allogeneic Hematopoietic Cell Transplantation (allo-HCT): Results from an Open-Label Cohort of a Phase 2 Trial

Posoleucel, Multivirus-Specific T-Cell (VST) Therapy, for Prevention of Clinically Significant Viral Infections in Allogeneic Transplant Recipients: Persistence of VSTs in an Open-Label Phase 2 Trial

Posoleucel for the Prevention of Clinically Significant Infections in High-Risk Allogeneic Hematopoietic Cell Transplant Recipients: Design of a Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Trial

Posoleucel for Adenovirus Infection in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: Design of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial

ALVR109, an Off-the-Shelf Partially HLA Matched SARS-CoV-2–Specific T Cell Therapy, to Treat Refractory Severe COVID-19 Pneumonia in a Heart Transplant Patient: Case Report

Posoleucel (ALVR105), an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Viral Infections Post-HCT: Results from an Open-Label Cohort of a Phase 2 Trial

Allogeneic, Off-the-Shelf, SARS-CoV-2-specific T cells Demonstrate Reactivity Against Emerging Variant Strains

Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of VIRALYM-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis After Allogeneic Haematopoietic Stem Cell Transplantation

Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High-Risk Patients with COVID-19

Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Pediatric and Adult Patients Following Allogeneic Hematopoietic Stem Cell Transplantation

Economic Burden and Health Resource Utilization Associated with Dsdna Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients

Allogeneic, Off-the-Shelf Multi-Virus Specific T-Lymphocytes for the Treatment of Virus-Associated Hemorrhagic Cystitis in the Post-HSCT Setting

Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States

Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation

Using Allogeneic, Off-the-Shelf, Sars-Cov-2-Specific T Cells to Treat High Risk Patients with COVID-19

Treatment of Severe, Drug-Refractory Viral Infections with Allogeneic, Off-the-Shelf Multi-Virus Specific T Cells in Patients Following HSCT: Results from a Phase 2 Study

Health Resource Utilization and Costs Associated with Multi-Virus infection after Allogeneic Hematopoietic Cell Transplantation

Economic and Clinical Burden of Respiratory Virus infections in Allogeneic Hematopoietic Cell Transplantation Recipients

"Mini” bank of only 8 donors supplies CMV-directed T cells to diverse recipients

Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections

Infusion of Cytotoxic T Lymphocytes for the Treatment of Viral Infections in Hematopoetic Stem Cell Transplant Patients

Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation

Antiviral T-cell Therapy

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Virus-specific T Cell Therapy Platform

Virus-specific T Cell Therapy Platform

Clinical Data

Preclinical Data

Preclinical Data

Health Economics / Outcomes Research Data

Health Economics / Outcomes Research Data

Viral Treatments - SOT

Viral Treatments - SOT

Hepatitis B Treatment/Cure

Hepatitis B Treatment/Cure

COVID-19 Treatment

COVID-19 Treatment

Respiratory Virus Treatment

Respiratory Virus Treatment

BK Virus Nephropathy – Kidney Transplant

BK Virus Nephropathy – Kidney Transplant

Multi-virus Prevention

Multi-virus Prevention

Viral Treatments - HCT

Viral Treatments - HCT

Hemorrhagic Cystitis Treatment

Hemorrhagic Cystitis Treatment

Adenovirus Treatment

Adenovirus Treatment

ALVR109

ALVR107

ALVR106

Posoleucel (ALVR105, Viralym-M)

Posoleucel (ALVR105, Viralym-M)

No results found.

Please try different keywords.

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?

AlloVir does not control and is not responsible for the content on the website you are about to visit. AlloVir is providing this link as a convenience, and this link does not imply AlloVir’s endorsement of any material on the website you are about to visit. Do you wish to continue?